[18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes.
Standard
[18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. / Würschmidt, Florian; Petersen, Cordula; Wahl, Andreas; Dahle, Jörg; Kretschmer, Matthias.
In: RADIAT ONCOL, Vol. 6, 2011, p. 44.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes.
AU - Würschmidt, Florian
AU - Petersen, Cordula
AU - Wahl, Andreas
AU - Dahle, Jörg
AU - Kretschmer, Matthias
PY - 2011
Y1 - 2011
N2 - At present there is no consensus on irradiation treatment volumes for intermediate to high-risk primary cancers or recurrent disease. Conventional imaging modalities, such as CT, MRI and transrectal ultrasound, are considered suboptimal for treatment decisions. Choline-PET/CT might be considered as the imaging modality in radiooncology to select and delineate clinical target volumes extending the prostate gland or prostate fossa. In conjunction with intensity modulated radiotherapy (IMRT) and imaged guided radiotherapy (IGRT), it might offer the opportunity of dose escalation to selected sites while avoiding unnecessary irradiation of healthy tissues.
AB - At present there is no consensus on irradiation treatment volumes for intermediate to high-risk primary cancers or recurrent disease. Conventional imaging modalities, such as CT, MRI and transrectal ultrasound, are considered suboptimal for treatment decisions. Choline-PET/CT might be considered as the imaging modality in radiooncology to select and delineate clinical target volumes extending the prostate gland or prostate fossa. In conjunction with intensity modulated radiotherapy (IMRT) and imaged guided radiotherapy (IGRT), it might offer the opportunity of dose escalation to selected sites while avoiding unnecessary irradiation of healthy tissues.
KW - Humans
KW - Male
KW - Aged
KW - Middle Aged
KW - Lymphatic Metastasis
KW - Radiotherapy Dosage
KW - Recurrence
KW - Neoplasm Staging
KW - Positron-Emission Tomography
KW - Tomography, X-Ray Computed/methods
KW - Carcinoma/mortality/pathology/radionuclide imaging/radiotherapy
KW - Choline/analogs & derivatives/diagnostic use
KW - Lymph Nodes/pathology/radiation effects
KW - Prostatic Neoplasms/mortality/pathology/radionuclide imaging/radiotherapy
KW - Radiotherapy Planning, Computer-Assisted/methods
KW - Radiotherapy, Intensity-Modulated
KW - Humans
KW - Male
KW - Aged
KW - Middle Aged
KW - Lymphatic Metastasis
KW - Radiotherapy Dosage
KW - Recurrence
KW - Neoplasm Staging
KW - Positron-Emission Tomography
KW - Tomography, X-Ray Computed/methods
KW - Carcinoma/mortality/pathology/radionuclide imaging/radiotherapy
KW - Choline/analogs & derivatives/diagnostic use
KW - Lymph Nodes/pathology/radiation effects
KW - Prostatic Neoplasms/mortality/pathology/radionuclide imaging/radiotherapy
KW - Radiotherapy Planning, Computer-Assisted/methods
KW - Radiotherapy, Intensity-Modulated
U2 - 10.1186/1748-717X-6-44
DO - 10.1186/1748-717X-6-44
M3 - SCORING: Journal article
VL - 6
SP - 44
JO - RADIAT ONCOL
JF - RADIAT ONCOL
SN - 1748-717X
ER -
